Description: Egetis Therapeutics AB (publ), a pharmaceutical company, focuses on projects in late-stage development for the treatment of serious diseases with unmet medical needs in the orphan drug segment. Its products pipeline includes Aladote, a drug to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning, which is in phase IIb/III clinical trial; and Emcitate, a drug for the treatment of MCT8 deficiency, a highly debilitating rare disease with no available treatment. The company was formerly known as PledPharma AB (publ) and changed its name to Egetis Therapeutics AB (publ) in December 2020. Egetis Therapeutics AB (publ) was incorporated in 2006 and is based in Stockholm, Sweden.
Home Page: www.egetis.com
0ABW Technical Analysis
Klara Norra Kyrkogata 26
Stockholm,
111 22
Sweden
Phone:
46 86 79 72 10
Officers
| Name | Title |
|---|---|
| Mr. Nicklas Westerholm | Chief Executive Officer |
| Mr. Torsten Almén | Founder |
| Dr. Ingemar Lundström Ph.D. | Founder |
| Dr. Louis Joseph Ignarro Ph.D. | Founder |
| Associate Prof. Heidi Brurok | Founder |
| Dr. Rob Towart | Founder |
| Dr. Yilmaz Mahshid Ph.D. | Chief Financial Officer |
| Dr. Katayoun Welin-Berger Ph.D. | Vice President of Operations |
| Dr. Jacques Näsström M.B.A., MBA, Ph.D. | Chief Scientific Officer |
| Dr. Karl Hard Ph.D. | VP and Head of Investor Relations & Communication |
Exchange: LSE
Country: GB : United Kingdom of Great Britain and Northern Ireland
Currency: Swedish krone (kr)
| GIC Sector: | Industrials |
|---|---|
| GIC Group: | Commercial & Professional Services |
| GIC Industry: | Commercial Services & Supplies |
| GIC Sub-Industry: | Environmental & Facilities Services |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 28 |